Non-Viral Gene Delivery Technologies Global Market Report 2026
상품코드:1957515
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
비바이러스성 유전자 도입 기술 시장 규모는 최근 급성장하고 있습니다. 2025년 45억 7,000만 달러에서 2026년에는 52억 8,000만 달러에 이르고, CAGR 15.5%의 성장이 전망되고 있습니다. 지난 수년간의 성장 요인으로는 바이러스성 전달 방식에 대한 의존도, 비바이러스성 전달 시약의 구하기 어려움, 유전자 치료 연구에 대한 관심 증가, 플라스미드 DNA 및 mRNA 전달 키트의 사용 증가, 전기 천공법 및 물리적 전달 기술의 채택 등을 들 수 있습니다. 등이 있습니다.
비바이러스성 유전자 도입 기술 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 92억 6,000만 달러에 이르고, CAGR은 15.1%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 첨단 지질 및 고분자 나노입자 개발, 사전 제형화된 나노입자 기술 확대, 유전자 편집 및 RNA 간섭(RNAi) 치료제에 대한 투자 증가, 개인 맞춤형 유전자 치료 솔루션에 대한 수요 증가, 고처리량 및 자동화된 전달 플랫폼의 통합 등을 들 수 있습니다. 예측 기간 동안 주요 동향으로는 지질 및 폴리머 기반 비바이러스성 전달 시스템의 채택 확대, CRISPR 및 Cas9 유전자 편집 용도의 성장, RNAi 및 DNA 백신 전달 플랫폼에 대한 수요 증가, 생체 외 및 생체 내 유전자 치료제 연구 확대, 세포 특이적 및 표적 유전자 전달 시약의 개발 등이 있습니다. 연구 확대, 세포 특이적 및 표적 지향적 유전자 전달 시약 개발 등을 꼽을 수 있습니다.
개인 맞춤형 의료에 대한 수요 증가는 향후 비바이러스성 유전자 전달 기술 시장의 성장을 가속화할 것으로 예측됩니다. 맞춤형 의료는 개인의 유전적 특성, 생활습관, 환경에 따라 예방, 진단, 치료를 최적화하는 의료입니다. 이러한 수요 증가는 유전체 분석 기술의 발전으로 정밀한 진단, 개인별 맞춤 치료, 환자별 최적의 치료 결과가 가능해졌기 때문입니다. 맞춤의료에 대한 관심이 높아지면서 바이러스 벡터의 위험을 피하면서 환자 고유의 치료용 유전자를 안전하고 유연하게 도입할 수 있는 비바이러스성 유전자 도입 기술에 대한 관심이 높아지고 있습니다. 예를 들어, 2024년 2월 미국 비영리단체 '맞춤의료연합'이 발표한 바에 따르면, FDA(미국 식품의약국)는 2023년 희귀질환에 대한 16개의 새로운 맞춤 치료법을 승인했습니다. 이는 2022년 6건에서 증가한 수치입니다. 이처럼 맞춤형 의료에 대한 수요 증가가 비바이러스성 유전자 도입 기술 시장의 성장을 견인하고 있습니다.
비바이러스성 유전자 전달 시장의 주요 기업들은 유전자 치료의 안전성과 성능을 향상시키기 위해 비바이러스성 유전자 의료 플랫폼과 같은 첨단 기술을 추진하고 있습니다. 비바이러스성 유전자 의료 플랫폼은 바이러스를 사용하지 않고 치료용 유전자나 핵산을 세포 내로 도입하기 때문에 면역반응이나 위험을 최소화하면서 다양한 질환에 대해 정확하고 제어된 전달이 가능합니다. 예를 들어, 2023년 10월 미국 유전자 치료제 전문 바이오 기업 제너레이션 바이오(Generation Bio)는 면역침강 DNA(iqDNA)를 발표했습니다. 이 회사의 폐쇄형 DNA(ceDNA)를 개량한 이 기술은 지질 나노입자(LNP)를 통해 전달함으로써 마우스와 비인간 영장류에서 사이토카인 프로파일과 내성이 변형된 mRNA와 유사한 특성을 보여 자연 면역의 감지를 피할 수 있습니다. iqDNA의 내약성 향상으로 제너레이션 바이오는 주력 사업인 혈우병 A 치료 프로그램을 포함한 모든 프로그램에서 iqDNA를 핵심 DNA 페이로드(payload)로 채택하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Non-viral gene delivery technologies are methods for transferring genetic material into cells without using viruses as carriers. These technologies reduce safety risks and immune responses associated with viral vectors while enabling precise and controlled gene delivery. Their primary purpose is to modify or regulate gene expression for applications such as treating genetic diseases and advancing cell-based therapies.
The main product types of non-viral gene delivery technologies include reagents and kits, delivery devices, and pre-formulated nanoparticles. Reagents and kits are ready-to-use chemical formulations designed to introduce genetic material into cells without viral involvement. Delivery can occur through various modes, including in vitro, in vivo, and ex vivo, using technologies such as electroporation, lipid-based transfection, polymer-based transfection, physical methods (microinjection and gene gun), and nanoparticle-mediated delivery. These technologies are applied in multiple areas, including gene therapy, DNA vaccines, RNA interference (RNAi), CRISPR/Cas9 gene editing, and protein expression. Key end users include biotechnology and biopharmaceutical companies, research and academic institutes, and other organizations involved in genetic research and therapeutics.
Tariffs have impacted the non-viral gene delivery technologies market by increasing the cost of imported reagents, nanoparticles, and delivery devices, affecting both research and clinical applications. Segments like pre-formulated nanoparticles and advanced delivery devices are most affected, particularly in North America and Europe where imports constitute a significant share. While tariffs have raised operational costs and slowed adoption, they have also encouraged domestic manufacturing, investment in local R&D, and innovation in cost-effective gene delivery technologies.
The non-viral gene delivery technologies market research report is one of a series of new reports from The Business Research Company that provides non-viral gene delivery technologies market statistics, including non-viral gene delivery technologies industry global market size, regional shares, competitors with a non-viral gene delivery technologies market share, detailed non-viral gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral gene delivery technologies industry. This non-viral gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The non-viral gene delivery technologies market size has grown rapidly in recent years. It will grow from $4.57 billion in 2025 to $5.28 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to reliance on viral delivery methods, limited availability of non-viral transfection reagents, growing interest in gene therapy research, increasing use of plasmid dna and mrna delivery kits, adoption of electroporation and physical delivery techniques.
The non-viral gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $9.26 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to development of advanced lipid and polymer nanoparticles, expansion of pre-formulated nanoparticle technologies, rising investment in gene editing and rnai therapeutics, increasing demand for personalized gene therapy solutions, integration of high-throughput and automated delivery platforms. Major trends in the forecast period include increasing adoption of lipid-based and polymer-based non-viral delivery systems, growth in crispr and cas9 gene editing applications, rising demand for rnai and dna vaccine delivery platforms, expansion of ex-vivo and in-vivo gene therapy research, development of cell-specific and targeted gene delivery reagents.
The surging need for personalized medicine is set to accelerate the non-viral gene delivery technologies market ahead. Personalized medicine tailors prevention, diagnosis, and therapy to an individual's distinct genetics, habits, and surroundings. This rising demand arises from progress in genomic sequencing, enabling precise diagnostics, customized treatments, and superior results suited to each patient. The heightened emphasis on personalized medicine spurs interest in non-viral gene delivery technologies, which provide secure, flexible ways to insert patient-specific therapeutic genes, avoiding viral vector hazards. For example, in February 2024, the Personalized Medicine Coalition, a US non-profit, noted that the FDA greenlit 16 new personalized therapies for rare diseases in 2023, up from 6 in 2022. Hence, the escalating demand for personalized medicine is propelling the non-viral gene delivery technologies market.
Key players in the non-viral gene delivery market are advancing cutting-edge options like non-viral genetic medicine platforms to enhance gene therapy safety and performance. A non-viral genetic medicine platform introduces therapeutic genes or nucleic acids into cells sans viruses, minimizing immune responses and risks, while allowing accurate, regulated delivery for diverse conditions. For instance, in October 2023, Generation Bio Co., a US biotech firm focused on genetic medicines, unveiled immune-quiet DNA (iqDNA). This enhanced version of their closed-ended DNA (ceDNA) dodges innate immune sensing, displaying cytokine profiles and tolerance akin to modified mRNA in mice and non-human primates via lipid nanoparticle (LNP) delivery. Thanks to iqDNA's enhanced tolerability, Generation Bio is adopting it as the core DNA payload across its programs, including the flagship hemophilia A initiative.
In September 2023, SOHM Inc., a US pharmaceutical company expert in generic and private-label drug production and distribution, purchased ABBIE Inc. for an undisclosed sum. This move bolsters SOHM's expertise in non-viral gene delivery technologies, equipping it to pioneer gene-editing innovations and grow its footprint in the expanding genetic therapeutics arena. ABBIE Inc. is a US-based gene-editing platform that transports genetic payloads through non-viral vectors.
Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.
North America was the largest region in the non-viral gene delivery technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the non-viral gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The non-viral gene delivery technologies market consists of revenues earned by entities by providing services such as genetic material formulation, delivery system development, and transfection optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-viral gene delivery technologies market also includes sales of lipid nanoparticles, polymer-based carriers, electroporation devices, and microinjection systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Non-Viral Gene Delivery Technologies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses non-viral gene delivery technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for non-viral gene delivery technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral gene delivery technologies market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Product: Reagents And Kits; Delivery Devices; Pre-Formulated Nanoparticles
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Increasing Adoption Of Lipid-Based And Polymer-Based Non-Viral Delivery Systems
4.2.2 Growth In Crispr And Cas9 Gene Editing Applications
4.2.3 Rising Demand For Rnai And Dna Vaccine Delivery Platforms
4.2.4 Expansion Of Ex-Vivo And In-Vivo Gene Therapy Research
4.2.5 Development Of Cell-Specific And Targeted Gene Delivery Reagents
5. Non-Viral Gene Delivery Technologies Market Analysis Of End Use Industries
5.1 Biotechnology Companies
5.2 Biopharmaceutical Companies
5.3 Research Institutes
5.4 Academic And University Laboratories
5.5 Contract Research Organizations (Cros)
6. Non-Viral Gene Delivery Technologies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Non-Viral Gene Delivery Technologies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Non-Viral Gene Delivery Technologies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Non-Viral Gene Delivery Technologies Market Size, Comparisons And Growth Rate Analysis
7.3. Global Non-Viral Gene Delivery Technologies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Non-Viral Gene Delivery Technologies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Non-Viral Gene Delivery Technologies Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.4. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression
9.5. Global Non-Viral Gene Delivery Technologies Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses
9.6. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Reagents And Kits, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Non-Viral Gene Delivery Technologies Market
12.1. China Non-Viral Gene Delivery Technologies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Non-Viral Gene Delivery Technologies Market
13.1. India Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Non-Viral Gene Delivery Technologies Market
14.1. Japan Non-Viral Gene Delivery Technologies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Non-Viral Gene Delivery Technologies Market
15.1. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Non-Viral Gene Delivery Technologies Market
16.1. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Non-Viral Gene Delivery Technologies Market
17.1. South Korea Non-Viral Gene Delivery Technologies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Non-Viral Gene Delivery Technologies Market
19.1. South East Asia Non-Viral Gene Delivery Technologies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Non-Viral Gene Delivery Technologies Market
20.1. Western Europe Non-Viral Gene Delivery Technologies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Non-Viral Gene Delivery Technologies Market
21.1. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22.1. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Non-Viral Gene Delivery Technologies Market
23.1. France Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25.1. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Non-Viral Gene Delivery Technologies Market
26.1. Eastern Europe Non-Viral Gene Delivery Technologies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Non-Viral Gene Delivery Technologies Market
27.1. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Non-Viral Gene Delivery Technologies Market
28.1. North America Non-Viral Gene Delivery Technologies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Non-Viral Gene Delivery Technologies Market
29.1. USA Non-Viral Gene Delivery Technologies Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Non-Viral Gene Delivery Technologies Market
31.1. South America Non-Viral Gene Delivery Technologies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Non-Viral Gene Delivery Technologies Market
32.1. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Non-Viral Gene Delivery Technologies Market
33.1. Middle East Non-Viral Gene Delivery Technologies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Non-Viral Gene Delivery Technologies Market
34.1. Africa Non-Viral Gene Delivery Technologies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Non-Viral Gene Delivery Technologies Market Regulatory and Investment Landscape
36. Non-Viral Gene Delivery Technologies Market Competitive Landscape And Company Profiles
